ribavirin has been researched along with Anemia, Hemolytic in 78 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.56) | 18.2507 |
| 2000's | 34 (43.59) | 29.6817 |
| 2010's | 41 (52.56) | 24.3611 |
| 2020's | 1 (1.28) | 2.80 |
| Authors | Studies |
|---|---|
| Ball, L; Brooks, L; Gish, R; Sulkowski, MS; Wasserman, R | 1 |
| Al-Judaibi, B; Carleton, BC; Drögemöller, BI; Ford, JA; Kim, RB; Lee, SS; Lin, JJ; Loucks, CM; Ramji, A; Ross, CJ; Schwarz, UI; Tam, E; Trueman, JN; Wright, GEB; Yoshida, EM | 1 |
| Abdel Baki, A; El Raziky, M; Mansour, SA; Shahin, RMH; Zayed, NA | 1 |
| Guo, H; Li, Z; Liu, Z; Qi, W; Sun, D; Wang, H; Wang, J; Wang, S; Wang, X; Zhang, Y; Zhao, P; Zhou, C; Zhu, L | 1 |
| Abunimeh, M; Cohen, DE; Davis, JW; Dumas, EO; Lagging, M; Söderholm, J; Vasanthakumar, A; Waring, JF; Zha, J | 1 |
| Akahane, T; Furukawa, M; Kaji, K; Kawaratani, H; Kitade, M; Kitagawa, K; Mitoro, A; Moriya, K; Namisaki, T; Okura, Y; Saikawa, S; Sato, S; Sawada, Y; Seki, K; Shimozato, N; Takaya, H; Yamao, J; Yoshiji, H | 1 |
| Ahn, YH; Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, DH; Lee, MJ; Park, H | 1 |
| Lee, TH; Patel, K; Tillmann, HL | 1 |
| Ali, RJ; Bonanzinga, S; Bowden, DS; Cheng, WS; Crawford, DH; Desmond, PV; Dore, GJ; Holmes, JA; Matthews, GV; McCaughan, GW; Roberts, SK; Sievert, W; Sundararajan, V; Thompson, AJ; Visvanathan, K; Weltman, MD | 1 |
| Chuang, WL; Dai, CY; Yu, ML | 1 |
| Holmes, JA; Matthews, GV; Thompson, AJ | 1 |
| Abdi, AM; Boglione, L; Cardellino, CS; Cariti, G; Caviglia, GP; Ciancio, A; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Rizzetto, M; Smedile, A; Strona, S; Troshina, G | 1 |
| Maliakkal, B; Soota, K | 1 |
| García-Álvarez, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Resino, S; Vázquez-Morón, S | 1 |
| Mahmoud, M; Morsy, KH; Zaghloul, A | 1 |
| Diago, M; Peño, L; Plana, L; Urquijo, JJ | 1 |
| Allegra, S; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G | 1 |
| Cao, P; Du, LT; Huang, JL; Ji, KM; Ji, YQ; Ma, YJ; Wu, CH; Zang, DY; Zhang, HD; Zhu, GL | 1 |
| Clayton, CW; Jimmerson, LC; Kiser, JJ; Kottilil, S; MaWhinney, S; Meissner, EG; Sims, Z | 1 |
| Enomoto, M; Hagihara, A; Hai, H; Kawada, N; Kawamura, E; Kozuka, R; Morikawa, H; Motoyama, H; Murakami, Y; Tamori, A; Teranishi, Y; Uchida-Kobayashi, S | 1 |
| Arias, A; Benítez-Gutiérrez, L; Citores, MJ; Cuervas-Mons, V; de Mendoza, C; Esposito, I; Requena, S; Soriano, V; Treviño, A | 1 |
| Azim, J; McCurdy, H; Moseley, RH | 1 |
| Boudreau, EF; Byrne, WR; Chung, KN; Cosgriff, T; Erlichman, MS; Gibbs, PH; Huggins, JW; Kim, KY; Kim, TT; Pittman, P; Rezvani, DF; Rusnak, JM | 1 |
| Amiot, X; Ancel, D; Chaslin-Ferbus, D; Garioud, A; Girot, R; Grange, JD; Hagege, I; Pol, S | 1 |
| Pockros, PJ; Shields, WW | 1 |
| Jain, MK; Zoellner, C | 1 |
| Albrecht, J; Bertelsen, AH; Brass, C; Fellay, J; Ge, D; Goldstein, DB; Gumbs, CE; Little, LD; McHutchison, JG; Muir, AJ; Qiu, P; Shianna, KV; Sulkowski, M; Thompson, AJ; Urban, TJ; Warner, A; Watson, M | 1 |
| Cardona-Meléndez, GM; DebRoy, S; Diaz, E; Kang, M; Kribs-Zaleta, C; Medina-Rios, L; Mubayi, A | 1 |
| Aguirrebengoa, K; Barreiro, P; Guardiola, JM; Labarga, P; Miralles, C; Miralles, P; Morello, J; Portu, J; Rodriguez-Novoa, S; Rubio, R; Soriano, V; Vispo, E | 1 |
| Afdhal, NH; Fellay, J; Fried, MW; Ge, D; Goldstein, DB; McHutchison, JG; Muir, AJ; Naggie, S; Patel, K; Shianna, KV; Thompson, AJ; Tillmann, HL; Urban, TJ | 1 |
| Brochot, E; Capron, D; Castelain, S; Duverlie, G; François, C; Nguyen-Khac, E | 1 |
| Bacon, BR; Chun, E; Halliman, D; Hammond, J; Hassanein, T; Heise, J; Lawitz, E; Muir, AJ; Poordad, F; Shiffman, ML | 1 |
| Kwo, PY; Vinayek, R | 1 |
| Dixit, NM; Krishnan, SM | 1 |
| Berg, T; Doehring, A; Geisslinger, G; Herrmann, E; Hofmann, WP; Lötsch, J; Müller, T; Sarrazin, C; Schlecker, C; Zeuzem, S | 1 |
| Hiramatsu, N; Iwasaki, M; Izumi, N; Kakinnuma, S; Kurosaki, M; Matsuura, K; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Tamori, A | 1 |
| Asahina, Y; Enomoto, N; Hoshioka, Y; Hosokawa, T; Itakura, J; Izumi, N; Kato, T; Kurosaki, M; Kuzuya, T; Matsuura, K; Mizokami, M; Nakanishi, H; Nishida, N; Sugauchi, F; Suzuki, Y; Takahashi, Y; Tamaki, N; Tanaka, K; Tanaka, Y; Tokunaga, K; Tsuchiya, K; Ueda, K; Yasui, Y | 1 |
| Arora, S; Deming, P | 1 |
| Mizokami, M; Sugiyama, M | 1 |
| Benito, JM; Clark, PJ; Goldstein, DB; McHutchison, JG; Morello, J; Naggie, S; Rallon, NI; Rodriguez-Novoa, S; Shianna, KV; Soriano, V; Thompson, AJ; Vispo, E | 1 |
| Baietto, L; Bonora, S; Calcagno, A; Cariti, G; Ciancio, A; Cusato, J; de Requena, DG; Di Perri, G; DʼAvolio, A; Marucco, DA; Rizzetto, M; Sciandra, M; Siccardi, M; Simiele, M; Smedile, A; Troshina, G | 1 |
| Bae, SH; Jun, DW; Lee, YJ; Tak, WY | 1 |
| Agnesod, D; Baietto, L; Boglione, L; Bonora, S; Calcagno, A; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Sciandra, M; Simiele, M; Turini, S | 1 |
| Bjøro, K; Dalgard, O; Eskesen, AN; Melum, E; Moghaddam, A; Ring-Larsen, H; Verbaan, H | 1 |
| Brochot, E; Capron, D; Castelain, S; Duchaussoy, I; Duverlie, G; François, C; Helle, F; Nguyen-Khac, E; Van Nhien, AN | 1 |
| Aghemo, A; Degasperi, E; Facchetti, F; Galmozzi, E; Lampertico, P | 1 |
| Calvaruso, V; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Grimaudo, S; Pipitone, RM | 1 |
| Gournay, J; Richou, C | 1 |
| Chan, KA; Chang, CH; Chen, KY; Lai, MY | 1 |
| Del Vecchio, C; Durante Mangoni, E; Marrone, A; Ruggiero, G; Saviano, D; Utili, R | 1 |
| Dresser, L; Knowles, SR; Matukas, L; Phillips, EJ | 1 |
| Dev, A; McHutchison, JG; Muir, A; Patel, K | 1 |
| Arroyo, J; Castro, FJ; González, H; Muñoz, H; Ríos, ME; Torres, EA | 1 |
| Bräu, N | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Takaki, S; Tsubota, A | 1 |
| Itoh, Y; Okanoue, T | 1 |
| Hayashi, J; Higashi, M; Ishibashi, H; Kajiwara, E; Kashiwagi, S; Maruyama, T; Matsui, Y; Mukai, T; Nagano, M; Nomura, H; Shimono, J; Tanimoto, H; Yamashita, N | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y | 1 |
| Kasahara, A | 1 |
| Fujisaki, K; Ido, A; Kubozono, O; Sakashita, H; Sho, Y; Tahara, K; Tsubouchi, H; Yamaguchi, K | 1 |
| Adamek, A; Adamek, J; Juszczyk, J | 1 |
| Boulestin, A; Chatelut, E; Durand, D; Esposito, L; Izopet, J; Kamar, N; Rostaing, L; Sandres-Saune, K; Selves, J; Stébenet, M | 1 |
| Chawla, S; Rivkin, AM | 1 |
| Adachi, K; Akagi, S; Furuta, K; Ishihara, S; Kinoshita, Y; Kohge, N; Mishiro, T; Miyake, T; Rumi, MA; Sato, S; Uchida, Y | 1 |
| Balestrieri, A; Balestrieri, C; Cauli, C; Chessa, L; Farci, P; Serra, G | 1 |
| Hagiwara, H; Haruna, Y; Hayashi, N; Hijioka, T; Hiramatsu, N; Ishibashi, K; Kanto, T; Kasahara, A; Katayama, K; Kato, M; Kubota, S; Kurashige, N; Mita, E; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tsuda, N; Yakushijin, T; Yoshihara, H | 1 |
| Civolani, A; Demelia, L; Murgia, D; Murru, A; Rizzetto, M; Sorbello, O | 1 |
| Ide, T; Kage, M; Maruyama, T; Okamura, T; Sata, M; Seki, R; Uyesaka, N | 1 |
| Terada, H | 1 |
| Duvnjak, M; Virovic Jukic, L; Wu, CH; Wu, GY | 1 |
| Dusheiko, G; Nelson, D; Reddy, KR | 1 |
| Martin, P; Saab, S | 1 |
| Ayi, K; Brugnara, C; Corrocher, R; De Franceschi, L; Fattovich, G; Manzato, F; Noventa, F; Solero, P; Stanzial, AM; Turrini, F | 1 |
| De Vos, M; Delanghe, JR; Leroux-Roel, G; Van Vlierbergh, H | 1 |
| Perry, CM; Scott, LJ | 1 |
| Dieterich, DT | 1 |
| Cosgriff, TM; Guang, MY; Hsiang, CM; Huggins, JW; LeDuc, JW; Meegan, JM; Smith, JI; Wang, QN; Wu, ZO; Zheng, ZM | 1 |
17 review(s) available for ribavirin and Anemia, Hemolytic
| Article | Year |
|---|---|
Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.
Topics: Anemia, Hemolytic; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genetic Markers; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Polymorphism, Single Nucleotide; Precision Medicine; Protease Inhibitors; Pyrophosphatases; Ribavirin | 2014 |
Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection.
Topics: Anemia, Hemolytic; Animals; Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Heme Oxygenase-1; Hemolysis; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Inflammation Mediators; Ribavirin; Treatment Outcome | 2014 |
Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Female; Genetic Variation; Genotype; Haplotypes; Hemoglobins; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Metabolism, Inborn Errors; Middle Aged; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Regression Analysis; Ribavirin; Treatment Outcome | 2015 |
Pharmacogenetics of ribavirin-induced anemia in HCV patients.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin | 2016 |
Role of ribavirin in HCV treatment response: now and in the future.
Topics: Administration, Oral; Anemia, Hemolytic; Antiviral Agents; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.
Topics: Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Taribavirin in the treatment of hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Prodrugs; Ribavirin | 2011 |
[Genome-wide association study on and the clinical application to chronic hepatitis C].
Topics: Anemia, Hemolytic; Antiviral Agents; Genome-Wide Association Study; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Pyrophosphatases; Racial Groups; Recombinant Proteins; Ribavirin | 2011 |
Recent trends in the treatment of chronic hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Precision Medicine; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral | 2012 |
[Treatment of chronic hepatitis C: side effects, tolerability and quality of life].
Topics: Anemia, Hemolytic; Antiviral Agents; Blood Cell Count; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Depressive Disorder; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Mental Disorders; Neutropenia; Prospective Studies; Quality of Life; Retrospective Studies; Ribavirin; Risk Factors; Thrombocytopenia; Time Factors | 2002 |
Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Ribavirin | 2002 |
Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Health Care Costs; Hepatitis C; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin; Risk Factors | 2005 |
[Drug-induced hemolytic anemia].
Topics: Anemia, Hemolytic; Anti-Bacterial Agents; Antigen-Antibody Complex; Antiviral Agents; Autoantibodies; Diagnosis, Differential; Glucosephosphate Dehydrogenase Deficiency; Haptens; Hemolytic-Uremic Syndrome; Humans; Methyldopa; Penicillins; Procainamide; Proton Pump Inhibitors; Purpura, Thrombotic Thrombocytopenic; Quinidine; Ribavirin | 2007 |
Ribavirin considerations in treatment optimization.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Time Factors; Viral Load | 2008 |
Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Topics: Adjuvants, Immunologic; Amino Acid Sequence; Anemia, Hemolytic; Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Molecular Sequence Data; Mood Disorders; Recombinant Proteins; Ribavirin | 2002 |
Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2002 |
9 trial(s) available for ribavirin and Anemia, Hemolytic
| Article | Year |
|---|---|
Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors | 2004 |
Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens.
Topics: Anemia, Hemolytic; Antiviral Agents; Female; Humans; Inosine Triphosphatase; Interferons; Interleukins; Male; Polymorphism, Genetic; Pyrophosphatases; Ribavirin | 2018 |
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isomerism; Male; Middle Aged; Oligopeptides; Ribavirin | 2014 |
Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2016 |
Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Epoetin Alfa; Erythrocytes; Erythropoietin; Female; Hematinics; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.
Topics: Adolescent; Adult; Anemia, Hemolytic; Antiviral Agents; Body Weight; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Impaired filterability of erythrocytes from patients with chronic hepatitis C and effects of eicosapentaenoic acid on the filterability.
Topics: Adult; Aged; Anemia, Hemolytic; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Eicosapentaenoic Acid; Erythrocyte Deformability; Erythrocyte Membrane; Erythrocytes; Hemorheology; Hepatitis C, Chronic; Humans; Interferon Type I; Japan; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2007 |
Factors influencing ribavirin-induced hemolysis.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Female; Haptoglobins; Hemoglobins; Hemolysis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phenotype; Platelet Count; Recombinant Proteins; Ribavirin; Risk Factors | 2001 |
Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome.
Topics: Anemia, Hemolytic; Double-Blind Method; Female; Fever; Follow-Up Studies; Hemorrhagic Fever with Renal Syndrome; Humans; Hypotension; Immunoglobulin M; Injections, Intravenous; Life Tables; Male; Oliguria; Orthohantavirus; Polyuria; Prognosis; Prospective Studies; Regression Analysis; Ribavirin | 1991 |
52 other study(ies) available for ribavirin and Anemia, Hemolytic
| Article | Year |
|---|---|
Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment.
Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Canada; Case-Control Studies; Female; Genome-Wide Association Study; Glycophorins; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Prospective Studies; Pyrophosphatases; Receptors, Calcitriol; Ribavirin; Risk Assessment; Risk Factors | 2021 |
ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.
Topics: Adult; Alleles; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Real-Time Polymerase Chain Reaction; Ribavirin; Treatment Outcome | 2017 |
The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.
Topics: Anemia, Hemolytic; Antiviral Agents; China; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotyping Techniques; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Pharmacogenomic Testing; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Recombinant Proteins; Ribavirin; Treatment Outcome | 2017 |
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.
Topics: Aged; Anemia, Hemolytic; Carnitine; Drug Therapy, Combination; Female; Hepatitis C; Humans; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome | 2019 |
Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea.
Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Leprosy; Male; Prevalence; Republic of Korea; Retrospective Studies; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2019 |
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Clinical Trials, Phase IV as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Inosine Triphosphatase; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrophosphatases; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin | 2014 |
Association between response to pegylated interferon/ribavirin therapy and ribavirin levels.
Topics: Anemia, Hemolytic; Antiviral Agents; Female; Hepatitis C; Humans; Male; Pyrophosphatases; Ribavirin | 2015 |
Reply: To PMID 24449403.
Topics: Anemia, Hemolytic; Antiviral Agents; Female; Hepatitis C; Humans; Male; Pyrophosphatases; Ribavirin | 2015 |
Difficult management of triple therapy for chronic hepatitis C in a patient on haemodialysis.
Topics: Anemia, Hemolytic; Antiviral Agents; Bacteremia; Blood Component Transfusion; Catheter-Related Infections; Drug Therapy, Combination; Glomerulonephritis; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Renal Dialysis; Ribavirin; Staphylococcal Infections; Thrombocytopenia | 2017 |
Rapid CO breath test screening of drugs for protective effects on ribavirin-induced hemolysis in a rabbit model: a pilot study.
Topics: Anemia, Hemolytic; Animals; Antiviral Agents; Breath Tests; Carbon Monoxide; Disease Models, Animal; Drug Evaluation, Preclinical; Erythrocyte Count; Erythrocytes; Female; Glutathione; Hemoglobins; Male; Pilot Projects; Protective Agents; Rabbits; Ribavirin | 2016 |
Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines.
Topics: Adenosine Triphosphate; Anemia, Hemolytic; Female; Guanosine Triphosphate; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Inosine Triphosphate; Male; Middle Aged; Nucleotides; Phenotype; Polymorphism, Single Nucleotide; Purines; Pyrophosphatases; Retrospective Studies; Ribavirin; Sofosbuvir | 2017 |
Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic; Antiviral Agents; Asian People; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Sofosbuvir | 2017 |
Impact of ITPA gene polymorphisms on the risk of ribavirin-induced haemolytic anaemia using interferon-free antivirals for chronic hepatitis C.
Topics: Adult; Aged; Alleles; Anemia, Hemolytic; Antiviral Agents; Disease Susceptibility; Female; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Retrospective Studies; Ribavirin | 2017 |
Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Hemochromatosis; Hemochromatosis Protein; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Interferon alpha-2; Interferon-alpha; Iron Overload; Male; Membrane Proteins; Middle Aged; Mutation; Phlebotomy; Polyethylene Glycols; Porphyria Cutanea Tarda; Recombinant Proteins; Ribavirin | 2008 |
Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Bradycardia; Cohort Studies; Creatinine; Drug-Related Side Effects and Adverse Reactions; Female; Hantaan virus; Hemorrhagic Fever with Renal Syndrome; Humans; Infusions, Intravenous; Korea; Male; Middle Aged; Ribavirin; Young Adult | 2009 |
Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin.
Topics: Adolescent; Adult; Anemia, Hemolytic; Anemia, Sickle Cell; Antiviral Agents; beta-Thalassemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Pilot Projects; Ribavirin; Treatment Outcome; Young Adult | 2009 |
Ribavirin analogs.
Topics: Anemia, Hemolytic; Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Humans; IMP Dehydrogenase; Mycophenolic Acid; Phenylurea Compounds; Ribavirin | 2009 |
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
Topics: Alleles; Anemia, Hemolytic; Antiviral Agents; Chromosomes, Human, Pair 20; Europe; Genetic Variation; Genome-Wide Association Study; Hemoglobins; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Polymorphism, Single Nucleotide; Pyrophosphatases; Racial Groups; Ribavirin; United States | 2010 |
Evaluating treatment of hepatitis C for hemolytic anemia management.
Topics: Anemia, Hemolytic; Antiviral Agents; Computer Simulation; Drug Therapy, Combination; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Models, Biological; Recombinant Proteins; Ribavirin | 2010 |
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Female; Genotype; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome | 2010 |
The next step for taribavirin.
Topics: Anemia, Hemolytic; Antiviral Agents; Hepatitis C, Chronic; Humans; Ribavirin | 2010 |
Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.
Topics: Anemia, Hemolytic; Antiviral Agents; Computational Biology; Drug Therapy, Combination; Erythrocyte Aging; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Mathematical Concepts; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Female; Genetic Association Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Membrane Transport Proteins; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin | 2011 |
Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Cohort Studies; Decision Trees; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reproducibility of Results; Retrospective Studies; Ribavirin; Severity of Illness Index | 2011 |
Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Creatinine; Drug Administration Schedule; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2011 |
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Cohort Studies; Female; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin | 2012 |
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.
Topics: Adult; Alleles; Anemia, Hemolytic; Antiviral Agents; Feasibility Studies; Female; Genotype; Hemoglobins; Hepatitis C; Humans; Inosine Triphosphatase; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Retrospective Studies; Ribavirin | 2012 |
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients.
Topics: Anemia, Hemolytic; Antiviral Agents; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Erythrocytes; Feasibility Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Phosphorylation; Quality Control; Recombinant Proteins; Ribavirin | 2012 |
Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Ribavirin; Scandinavian and Nordic Countries; Treatment Outcome | 2012 |
A new tool to study ribavirin-induced haemolysis.
Topics: Adenosine Triphosphate; Adult; Anemia, Hemolytic; Dipyridamole; Drug Evaluation, Preclinical; Drug Therapy, Combination; Erythrocytes; Glutathione; Hematologic Tests; Hemolysis; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon alpha-2; Interferon-alpha; Poliovirus; Polyethylene Glycols; Prodrugs; Recombinant Proteins; Ribavirin; RNA, Viral | 2012 |
Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms.
Topics: Alleles; Anemia, Hemolytic; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Polymerase Chain Reaction; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Sensitivity and Specificity | 2013 |
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Pyrophosphatases; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Treatment Outcome | 2013 |
Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Recombinant Proteins; Ribavirin | 2003 |
Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic; Antiviral Agents; Canada; Disease Outbreaks; Female; Humans; Hypocalcemia; Male; Middle Aged; Ribavirin; Severe Acute Respiratory Syndrome | 2003 |
Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions.
Topics: Anemia, Hemolytic; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Male; Prognosis; Ribavirin; Treatment Outcome | 2003 |
Folic acid supplementation does not prevent ribavirin-induced anemia.
Topics: Anemia, Hemolytic; Antiviral Agents; Female; Folic Acid; Haptoglobins; Hemoglobins; Hepatitis C; Humans; Interferons; Male; Middle Aged; Ribavirin | 2003 |
Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2004 |
Ribavirin-induced hemolytic anemia in chronic hepatitis C patients.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
Factors contributing to ribavirin-induced anemia.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk Factors | 2004 |
Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin | 2004 |
How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C.
Topics: Administration, Oral; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Medicine, Kampo; Middle Aged; Retrospective Studies; Ribavirin | 2004 |
[Incidence of haemolytic anaemia during combination therapy of chronic hepatitis C with interferon alpha-2b and ribavirin].
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Poland; Recombinant Proteins; Ribavirin; Time Factors | 2004 |
Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Cytokines; Female; Hepatitis C, Chronic; Humans; Iron; Iron Overload; Kidney Transplantation; Liver; Liver Cirrhosis; Male; Middle Aged; Postoperative Complications; Ribavirin; Transferrin | 2005 |
Hemolytic anemia during 24 weeks of ribavirin and interferon-alpha2b combination therapy does not influence the cardiac function of patients with viral hepatitis C.
Topics: Anemia, Hemolytic; Drug Therapy, Combination; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Natriuretic Peptide, Brain; Recombinant Proteins; Ribavirin | 2006 |
Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Drug Combinations; Female; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2006 |
Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Disease Progression; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2006 |
Tolerability of Peg interferon-alpha2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Drug Tolerance; Female; Glucosephosphate Dehydrogenase Deficiency; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Human uridine-cytidine kinase phosphorylation of ribavirin: a convenient method for activation of ribavirin for conjugation to proteins.
Topics: Anemia, Hemolytic; Asialoglycoproteins; Drug Delivery Systems; Hepacivirus; Hepatitis C; Humans; Liver; Nucleoside-Phosphate Kinase; Orosomucoid; Phosphorylation; Ribavirin | 2008 |
Hemolytic anemia and the treatment of chronic hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 1999 |
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.
Topics: Adenosine Triphosphate; Adult; Anemia, Hemolytic; Anion Exchange Protein 1, Erythrocyte; Antiviral Agents; Carrier Proteins; Complement C3; Erythrocyte Membrane; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Immunoglobulin G; Interferons; K Cl- Cotransporters; Male; Middle Aged; Oxidative Stress; Reticulocyte Count; Ribavirin; Sodium-Potassium-Exchanging ATPase; Symporters | 2000 |
Ribavirin: new preparation. An advance, but still no cure-all.
Topics: Anemia, Hemolytic; Antiviral Agents; Clinical Trials as Topic; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Europe; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; United States | 2000 |